Schizophrenia is a life‐threatening disease associated with mortality rates that are two to
three times higher than those expected/observed in the general population. It is associated …

Context Excess mortality from heart disease is observed in patients with severe mental
disorder. This excess mortality may be rooted in adverse effects of pharmacological or …

BACKGROUND: Schizophrenia has been associated with a rate of premature mortality that
is 2 to 3 times higher than that in the general population. Although the role of cancer in this …

Objective: To characterize the epidemiology of schizophrenia. Method: Narrative literature
review. Results: Each year 1 in 10 000 adults (12 to 60 years of age) develops …

A study of mortality for all patients with a first hospital diagnosis of schizophrenia in
Stockholm County, Sweden, during 1973 to 1995 was performed, by linking the in-patient …

Antipsychotics are effective in preventing relapses of schizophrenia, but it is generally
believed that their long‐term use is harmful for patients' physical well‐being. However, there …

Cardiovascular disease (CVD), which includes coronary heart, cerebrovascular, and
peripheral vascular disease, is the leading cause of death in the United States and most …

Background Severe mental illness (SMI; schizophrenia, bipolar disorders (BDs), and other
nonorganic psychoses) is associated with increased risk of cardiovascular disease (CVD) …

Context Polypharmacy is widely used in the treatment of schizophrenia, although it is
believed to have major adverse effects on the well-being of patients. Objective To …

Background Clozapine is the most efficacious treatment for schizophrenia and is associated
with lower overall mortality than are other antipsychotic drugs, despite the risk of …